Previous Article | Next Article ![]()
Journal of Virology, October 2007, p. 10437-10450, Vol. 81, No. 19
0022-538X/07/$08.00+0 doi:10.1128/JVI.00399-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Protein
Ankur H. Shah,1,2 and
Cathleen Carlin1,2,3*
Department of Physiology and Biophysics,1 Molecular Virology Training Program,2 Case Western Reserve University Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-49703
Received 23 February 2007/ Accepted 9 July 2007
Early region 3 genes of human adenoviruses contribute to the virus life cycle by altering the trafficking of cellular proteins involved in adaptive immunity and inflammatory responses. The ability of early region 3 genes to target specific molecules suggests that they could be used to curtail pathological processes associated with these molecules and treat human disease. However, this approach requires genetic dissection of the multiple functions attributed to early region 3 genes. The purpose of this study was to determine the role of targeting on the ability of the early region 3-encoded protein RID
to downregulate the EGF receptor. A fusion protein between the RID
cytoplasmic tail and glutathione S-transferase was used to isolate clathrin-associated adaptor 1 and adaptor 2 protein complexes from mammalian cells. Deletion and site-directed mutagenesis studies showed that residues 71-AYLRH of RID
are necessary for in vitro binding to both adaptor complexes and that Tyr72 has an important role in these interactions. In addition, RID
containing a Y72A point mutation accumulates in the trans-Golgi network and fails to downregulate the EGF receptor when it is introduced into mammalian cells as a transgene. Altogether, our data suggest a model where RID
is trafficked directly from the trans-Golgi network to an endosomal compartment, where it intercepts EGF receptors undergoing constitutive recycling to the plasma membrane and redirects them to lysosomes.
Published ahead of print on 18 July 2007.
Present address: Technology Transfer Branch, National Cancer Institute, Executive Plaza South, Suite 450, 6120 Executive Boulevard, Bethesda, MD 20892.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»